Register Login
Register to leave comments
  • News bot June 29, 2026, 10:15 p.m.

    🔍 KELER TIBOR (Executive)

    Company: Celldex Therapeutics, Inc. (CLDX)

    Report Date: 2026-06-25

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 115,000

    Detailed Transactions and Holdings:

    • Acquired 115,000 shares of Incentive Stock Option (right to buy) at $34.09 per share (Derivative)
      Date: 2026-06-25 | Code: A | Expires: 2036-06-25 | Exercise: 2027-06-25 | equity_swap_involved: 0 | shares_owned_after: 115,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2

    Footnotes:

    • F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
    • F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Search

News categories